• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Rep . Pulmonary diffusing capacity among individuals recovering from mild to moderate COVID-19: a cross-sectional study

tetano

Editor, Senior Moderator
Sci Rep


. 2024 Nov 5;14(1):26767.
doi: 10.1038/s41598-024-74404-6. Pulmonary diffusing capacity among individuals recovering from mild to moderate COVID-19: a cross-sectional study

Dana Yelin[SUP] 1 2 [/SUP], Nassem Ghantous[SUP] 3 [/SUP], Muhammad Awwad[SUP] 3 [/SUP], Vered Daitch[SUP] 4 [/SUP], Talya Kalfon[SUP] 5 [/SUP], Michal Mor[SUP] 5 [/SUP], Shira Buchrits[SUP] 6 [/SUP], Yair Shafir[SUP] 7 [/SUP], Irit Shapira-Lichter[SUP] 8 [/SUP], Leonard Leibovici[SUP] 5 4 [/SUP], Dafna Yahav[SUP] 9 5 [/SUP], Ili Margalit[SUP] 9 5 [/SUP], Dorit Shitenberg[SUP] 10 11 [/SUP]



Affiliations
Abstract

Impaired pulmonary diffusing capacity for carbon monoxide (DLCO) following COVID-19 has been consistently reported among individuals recovering from severe-critical infection. However, most long COVID cases follow non-severe COVID-19. We assessed DLCO among individuals with long COVID recovering from mild to moderate acute illness. A cross-sectional study of adults with long COVID, assessed at a COVID recovery clinic > 3 months following the onset of acute infection, during 2020-2021. Participants subjectively ranked their dyspnea severity based on its impact on their daily living and underwent comprehensive pulmonary function testing (PFT). Clinical correlates for impaired DLCO (defined as < 80%) were assessed using multivariable logistic regression models. A total of 458 individuals, their mean age 45 (SD 16) and 246 (54%) of whom are women, were evaluated at an average of ~ 4 months following acute COVID-19. The most frequent PFT impairment was reduced DLCO, identified among 67 (17%) of the cohort. Clinical correlates of impaired DLCO included women (odds ration [OR] 3.64, 95% confidence interval [CI] 1.78-7.45, p < 0.001), cigarette smoking (OR 2.25, 95% CI 1.14-4.43, p = 0.019), and moderate-severe dyspnea (OR 2.77, 95% CI 1.39-5.50, p = 0.004). BMI inversely correlated with DLCO (OR 0.90, 95% CI 0.85-0.96 per 1 unit, p = 0.002). Impaired DLCO was not uncommon among individuals recovering from mild to moderate COVID-19. Women are at a greater risk, and subjective dyspnea correlated with impaired DLCO. Clinicians can rely on self-reported significant dyspnea to guide further assessment.

Keywords: Long COVID; Post-COVID; Pulmonary function testing.

 
Back
Top Bottom